Uptake of long chain fatty acids is regulated by dynamic interaction of FAT/CD36 with cholesterol/sphingolipid enriched microdomains (lipid rafts) by unknown
BioMed CentralBMC Cell Biology
ssOpen AcceResearch article
Uptake of long chain fatty acids is regulated by dynamic interaction 
of FAT/CD36 with cholesterol/sphingolipid enriched microdomains 
(lipid rafts)
Robert Ehehalt*, Richard Sparla, Hasan Kulaksiz, Thomas Herrmann, 
Joachim Füllekrug and Wolfgang Stremmel
Address: Department of Gastroenterology, University Hospital Heidelberg, INF 410, 69120 Heidelberg, Germany
Email: Robert Ehehalt* - robert_ehehalt@med.uni-heidelberg.de; Richard Sparla - richard_sparla@med.uni-heidelberg.de; 
Hasan Kulaksiz - thomas.herrmann@med.uni-heidelberg.de; Thomas Herrmann - hasan.kulaksiz@uniklinik-ulm.de; 
Joachim Füllekrug - joachim.fuellekrug@med.uni-heidelberg.de; Wolfgang Stremmel - wolfgang_stremmel@med.uni-heidelberg.de
* Corresponding author    
Abstract
Background: Mechanisms of long chain fatty acid uptake across the plasma membrane are
important targets in treatment of many human diseases like obesity or hepatic steatosis. Long chain
fatty acid translocation is achieved by a concert of co-existing mechanisms. These lipids can
passively diffuse, but certain membrane proteins can also accelerate the transport. However, we
now can provide further evidence that not only proteins but also lipid microdomains play an
important part in the regulation of the facilitated uptake process.
Methods: Dynamic association of FAT/CD36 a candidate fatty acid transporter with lipid rafts was
analysed by isolation of detergent resistant membranes (DRMs) and by clustering of lipid rafts with
antibodies on living cells. Lipid raft integrity was modulated by cholesterol depletion using methyl-
β-cyclodextrin and sphingolipid depletion using myriocin and sphingomyelinase. Functional analyses
were performed using an [3H]-oleate uptake assay.
Results: Overexpression of FAT/CD36 and FATP4 increased long chain fatty acid uptake. The
uptake of long chain fatty acids was cholesterol and sphingolipid dependent. Floating experiments
showed that there are two pools of FAT/CD36, one found in DRMs and another outside of these
domains. FAT/CD36 co-localized with the lipid raft marker PLAP in antibody-clustered domains at
the plasma membrane and segregated away from the non-raft marker GFP-TMD. Antibody cross-
linking increased DRM association of FAT/CD36 and accelerated the overall fatty acid uptake in a
cholesterol dependent manner. Another candidate transporter, FATP4, was neither present in
DRMs nor co-localized with FAT/CD36 at the plasma membrane.
Conclusion: Our observations suggest the existence of two pools of FAT/CD36 within cellular
membranes. As increased raft association of FAT/CD36 leads to an increased fatty acid uptake,
dynamic association of FAT/CD36 with lipid rafts might regulate the process. There is no direct
interaction of FATP4 with lipid rafts or raft associated FAT/CD36. Thus, lipid rafts have to be
considered as targets for the treatment of lipid disorders.
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Uptake of long chain fatty acids (LCFAs) is important for
many cellular functions and the understanding of the
uptake mechanisms is an important target for treatment
of lipid disorders [1-4]. The molecular mechanisms of
fatty acid transport across the plasma membrane are still
a matter of debate and the predominating mechanism
likely differs from cell to cell (for reviews see [5-8]). In
general, two possible groups of mechanisms are dis-
cussed: simple diffusion and saturable transport processes.
Whereas the uptake based on the passive diffusion process
depends on the activity of intracellular metabolism creat-
ing a transmembrane downhill concentration gradient;
the saturable process is regulated by expression of certain
proteins and lipids at the plasma membrane. Much effort
has been spent to identify candidate proteins that are
directly involved in the facilitated fatty acid uptake mech-
anism. So far four candidates (FABPpm, FAT/CD36, FATP
family proteins, caveolin-1) have been discussed [9-11].
Whereas FAT/CD36 and FABPpm are membrane associ-
ated fatty acid binding proteins that are thought to medi-
ate their dissociation from albumin and accumulation at
the outer leaflet of the plasma membrane [12], followed
by flip-flop across the phospholipid bilayer to the
cytosolic site; it has been suggested that FATPs are real
transporters directly involved in the uptake process of
LCFAs across the membrane bilayer [5]. However, recent
data from our laboratory suggest that this group of pro-
teins are rather enzymes that indirectly facilitate the trans-
location process by encompassing acyl-coA activity [13].
The composition of membrane lipids also modulates fatty
acid uptake. In particular, there is increasing evidence that
cholesterol is of crucial importance. Cholesterol depletion
in 3T3 adipocytes, HMEC, HEK293 or HepG2 cells
decreased LCFA uptake and this effect was reversible after
re-addition of cholesterol [14-17]. Caveolin-1 has been
suggested to regulate the cholesterol content of the
plasma membrane [8,18] and LCFA uptake. Caveolin-1
can bind LCFAs [10]. Caveolin-1 knock out mice showed
a reduced mass of adipocytes and increased serum free
fatty acids, indicating that LCFA uptake into adipocytes
might be impaired [19]. LCFA uptake is increased by cave-
olin-1 overexpression and inhibited in caveolin-1 knock-
out mouse fibroblasts [20] or by expression of the
dominant negative caveolin-1 mutant CAVDGV [16]. Inter-
estingly, the inhibitory effects of CAVDGV can be reversed
by replenishing the cell membranes with cholesterol and
can be mimicked by methyl-β cyclodextrin treatment [21].
All these studies point out that cholesterol is critically
involved in LCFA uptake. However, little is known about
the mechanisms by which cholesterol modulates this
process. We have previously hypothesized that the associ-
ation of FAT/CD36 with lipid rafts might determine this
process [8]. Rafts are lateral assemblies of sphingolipids
and cholesterol within cellular membranes involved in
compartmentalization of membrane processes [22]. Bio-
chemically, lipid raft constituents are characterized by
their insolubility in low concentration of detergents such
as Triton X-100 [23]. In this regard, it has been demon-
strated that a fraction of FAT/CD36 associates with deter-
gent-resistant membranes (DRMs) in a cholesterol-
dependent manner [16]. The reduction of overall LCFAs
uptake by cholesterol depletion was as effective as the spe-
cific inhibition of the FAT/CD36 function by sulfo-N-suc-
cinimidyl oleate (SSO). Simultaneous treatments had no
additional effect, suggesting that both procedures target
the same cellular compartment [16].
The most straightforward interpretation of these findings
is that there are two pools of FAT/CD36 at the plasma
membrane, one associated with lipid rafts, in which
LCFAs are transported, and another outside of rafts, where
no transport occurs. That means, FAT/CD36 has to reside
in lipid rafts to facilitate FA uptake. Cholesterol depletion
would shift FAT/CD36 into the surrounding lipid bilayer
and make this protein non-functional. If FAT/CD36 facil-
itated uptake of fatty acids requires that the receptor is
associated with lipid rafts, then regulation of this associa-
tion may represent a mechanism by which cellular uptake
of fatty acids can be regulated. In this paper we provide
evidence demonstrating that association of FAT/CD36
with lipid rafts is critical for the uptake process to occur.
Methods
Reagents and antibodies
Methyl-β-cyclodextrin, sphingomyelinase and myriocin
were from Sigma. Antibodies used were mouse anti-pla-
centa alkaline phosphatase (PLAP) (Dako Cytomation),
rabbit anti-PLAP [24]; rabbit anti-FATP4 (C4 anti FATP4
described in [13]); mouse anti-FLAG (Sigma), Cy5 and
Cy3 donkey anti-mouse/rabbit (Jackson Immuno
Research); mouse monoclonal antibody anti GFP 3E6
(Invitrogen); rabbit anti GFP KG77 [25]; mouse anti-FAT/
CD36 (Biosource).
Constructs
GFP-FATP4 have been described previously [13]. CD36-
FLAG was kindly provided by Douglas M. Lubin, Wash-
ington University School of Medicine, St. Louis, MO. GFP-
TMD is a membrane anchored version of the green fluo-
rescent protein. The signal sequence of human CD8
(MALPVTALLLPLALLLHAARP) is followed by an epitope
tag (VSV-G; YTDIEMNRLGK). Next is EGFP, followed by a
16 amino acid glycosylation tag from human rhodopsin
(NGTEGPNFYVPFSNAT) and the transmembrane
domain of podocalyxin (EFEDRFSMPLIITIVCMASFLL-
LVAALYGCCHRK). This plasmid is identical to the con-
struct GFP-tail described in [26] except that thePage 2 of 12
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non-raft protein [26].
Oleate uptake
Cumulative uptake of oleate was based on Stremmel and
Berk [27]. Adherent cells were incubated for 5 min at
37°C with [3H]-oleate solution 170 μM (0.68 μCi/ml
[3H]-oleate (Amersham)) BSA fatty acid free (Sigma) in
PBS; After stopping and washing with ice-cold 0.5% BSA
in PBS, cells were lysed with 1 M NaOH and aliquots ana-
lyzed for protein concentration (Biorad) and radioactivity
by scintillation counting as before [13].
Cells, transient transfection, cholesterol/sphingolipid 
depletion
COSJ (ATCC CRL-1651) and Vero (CCL-81) cells were
maintained under standard tissue culture conditions with
the appropriate culture media (COSJ: D-MEM Invitrogen
4,5 g glucose/L 10% FBS 2 mM L-Glutamine and Vero: D-
MEM Invitrogen 1 g glucose/L 5% FBS 2 mM L-
Glutamine). Cells grown to near confluency (10 cm2)
were transfected with 4 μg plasmid-DNA and 10 μl lipo-
fectamine 2000 (Invitrogen). Analysis was performed 16–
20 h hours after transfection. For cholesterol depletion the
cells were treated for 30 min with 10 mM methyl-β-cyclo-
dextrin (MβCD) in DMEM. Cholesterol determinations
were done using the Amplex Red Cholesterol Assay kit
(Molecular Probes). For inhibition of sphingolipid syn-
thesis the cells were seeded at a density of 0.2 × 106 in 10
cm2 dishes and were grown for 3 d in complete medium
in the presence of 5 μM myriocin. During this period the
medium was changed once. Growing COS cells in the
presence of myriocin for a longer time caused the cells to
detach and undergo apoptosis. The extent of sphingoli-
pid-depletion was estimated microscopically on cells
incubated for 30 min with 25 μg/ml of rhodamine-conju-
gated cholera toxin subunit B (Rh-CTB) (Molecular
Probes) at 4°C, which was followed by a wash and subse-
quent fixation in 4% paraformaldehyde in PBS (PFA). The
expression of FATP4 and FAT/CD36 for the different con-
ditions were in initial experiments by Western blotting
and found not to differ significantly (data not shown).
Immunofluorescence and antibody-induced patching
For immunofluorescence microscopy, cells were fixed for
4 min with 4% PFA at 8°C followed by an incubation in
methanol at -20°C for 4 min. Fixed cells were incubated
for 1 h at room temperature with the appropriate dilution
of antibodies in PBS/0.2% gelatine (see below). After
three washes with PBS/0.2% gelatine they were incubated
with the respective secondary antibodies in PBS/0.2% gel-
atine for 1 h at room temperature.
To aggregate raft proteins the respective antibodies were
diluted in CO2 independent medium (GIBCO) contain-
ing 2 mg/ml BSA. The polyclonal antibodies against PLAP
were diluted 1:35; the monoclonal anti-GFP (3E6) and
anti-FAT/CD36 1:50. The cells were incubated for 45 min
with the respective combination of antibodies at 10°C,
briefly washed and further incubated for 45 min at 10°C
with mixed fluorescently labelled secondary antibodies.
Cy3-labelled secondary antibodies were diluted 1:500,
and the Cy5-labelled ones 1:100. The cells were fixed as
described above. Fluorescent images were acquired on an
Olympus microscope and arranged with Adobe Pho-
toshop.
Preparation of detergent resistant membranes (DRMs)
Detergent extraction with Triton X-100 was performed as
described before for N2a cells [25]. Cells were grown in
3.5 cm dishes, transfected and 10–12 h later washed once
with PBS and scraped on ice into 1.5 ml homogenisation
buffer (250 mM Sucrose, 10 mM Hepes, 2 mM EDTA) and
after centrifugation (5 min 2000 rpm) cell pellets were
homogenized in homogenisation buffer containing 20
μg/ml each of chymostatin, leupeptin, antipain and pep-
statin A (Sigma) through a 26 G needle and centrifuged
for 5 min at 3000 rpm. The postnuclear supernatant was
subjected to extraction for 30 min at 4°C in 1% Triton X-
100. The extracts were adjusted to 40% OptiPrep (Axis-
Shield) and overlaid in a TLS 55 centrifugation tube with
30% OptiPrep/TNE, and TNE (25 mM Tris-HCl, pH 7.4,
150 mM NaCl, 2 mM EDTA old protocol/25 mM Tris-
HCl, pH 10.8, 150 mM NaCl, 5 mM EDTA new protocol
since 03.2007). The gradients were centrifuged at 400000
g in a Beckman SW41 rotor for 20 h at 4°C. Fractions were
obtained and used for Western blotting as described [16]
and protein levels quantified by densitometry.
Statistical analysis
All values are reported as mean and standard error of the
mean (SEM). The Kruskal-Wallis test was used to test for
statistical significance. Probability values of p < 0.05 were
set as threshold for statistical significance.
Results
Cholesterol depletion inhibits long chain fatty acid uptake 
in COS cells
To study the role of lipid rafts in long chain fatty acid
uptake we first analyzed again the effect of cholesterol
depletion also in COS cells. Cholesterol depletion was
done by treatment with the complexing agent methyl-β-
cyclodextrin (MβCD) that extracts plasma membrane
cholesterol. Immediately prior to testing uptake of [3H]-
oleic acid, COS cells were treated with 10 mM MβCD for
30 min. By this the cholesterol levels could be reduced to
50% of those of control cells. To easily monitor the role of
FAT/CD36 in fatty acid uptake cells were transiently tran-
fected with cDNA of FAT/CD36. Using lipofectamine as a
mediator up to 50% of cells could be transfected. Overex-Page 3 of 12
(page number not for citation purposes)
BMC Cell Biology 2008, 9:45 http://www.biomedcentral.com/1471-2121/9/45pression of FAT/CD36 resulted in an increased overall
uptake of [3H]-oleic acid by >20% within 5 min (Figure
1). Depletion of cholesterol with MβCD decreased fatty
acid uptake by >50% in both control cells and FAT/CD36
transfected cells (Figure 1). These results show again that
cholesterol is critically involved in [3H]-oleate uptake.
Inhibition of sphingolipid synthesis decreases LCFA uptake
Rafts are cholesterol and sphingolipid-enriched microdo-
mains. To find out whether sphingolipids are also impor-
tant for LCFA uptake, we tested the effect of inhibition of
sphingolipid biosynthesis.
COS cells were cultured in the presence of 5 μM myriocin,
which inhibits the first step of de novo ceramide synthesis
by interacting with the serine-palmitoyl transferase or
treated with 1 U of sphingomyelinase that is supposed to
deplete plasma membrane sphingolipids. Cells were
either treated for 3 d with myriocin before cotransfection
of FAT/CD36 and FATP4 or treated 1 d after cotransfec-
tion for 15 min with 1 U of sphingomyelinase. [3H]-
oleate uptake within 3 min was measured. Both treat-
ments resulted in a reduction of [3H]-oleate uptake by 17
± 3% (myriocin) and 15 ± 2% (sphingomyelinase),
respectively (Figure 2A). The ganglioside GM1 localizes to
lipid rafts and its plasma membrane level is altered by
inhibition of ceramide synthesis [28]. We monitored the
effect of myriocin and sphingomyelinase by staining of
the ganglioside GM1 with rhodamine-conjugated cholera
toxin subunit B (Rh-CTB). Myriocin treatment led to a
decrease in staining, suggesting a decreased amount of
total sphingolipids (Figure 2B). Sphingomyelinase
resulted in similar results (data not shown). Thus, [3H]-
oleate uptake can also be altered by depletion of sphingol-
ipids.
Cholesterol depletion inhibits [3H]-oleate uptakeFigure 1
Cholesterol depletion inhibits [3H]-oleate uptake. COS cells were transiently transfected with FAT/CD36 and treated 
with 10 mM MβCD leading to a ~50% decrease in total cellular cholesterol (not shown). Afterwards [3H]-oleate uptake within 
5 min was analysed. FAT/CD36 increased [3H]-oleate uptake significantly (p < 0.05). Cholesterol depletion decreased overall 
fatty acid uptake to less then 50% of control cells (p < 0.05). Data are expressed as mean and SEM of at least n = 6 experi-
ments. The ratio has been arbitrarily set to 100% in cells that were not cholesterol depleted.Page 4 of 12
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Myriocin and sphingomyelinase treatment decreases [3H]-oleate uptakeFigure 2
Myriocin and sphingomyelinase treatment decreases [3H]-oleate uptake. COS cells were either grown before 
cotransfection of FAT/CD36 and FATP4 for 3 d in the presence or absence (control) of 5 μM myriocin or were treated after 
co-transfection for 15 min with 1 U sphingomyelinase. (A) Overexpressing FAT and FATP4 increased [3H]-oleate uptake signif-
icantly (p < 0.05). Myriocin and sphingomyelinase treatment inhibited [3H]-oleate uptake significantly (p < 0.05). Data are 
expressed as mean and SEM from n = 3 independent experiments. (B) Staining of COS cells with Rh-CTB after 3 d treatment 
with 5 μM myriocin. The amount of the ganglioside GM1 on the surface is reduced after myriocin treatment. Bar: 200 μm. 
Both images in panel B were recorded with the same exposure time.
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and segregates from non-raft marker GFP-TMD
Lipid rafts are small and highly dispersed at the plasma
membrane. In fibroblasts using photonic force micros-
copy it has been found that individual rafts have a size of
about 50 nm and contain approximately 3000 sphingoli-
pid molecules and probably a subset of 10–30 protein
molecules [29]. Therefore they are too small to be
resolved by light microscopy. However, raft and non-raft
markers can be cross-linked with antibodies into visible
patches [25,30,31]. Raft proteins co-patch with each other
and segregate away from non-raft markers. Thus, cross-
linking with antibodies can be used as a tool to analyse
raft association. We therefore tested whether antibody
cross-linking induces co-patching of FAT/CD36 with a raft
marker, the glycosyl phosphatidylinositol (GPI)-
anchored protein placental alkaline phosphatase (PLAP).
As a non-raft marker, we used GFP-TMD. COS cells were
transfected and the respective plasma membrane antigens
cross-linked with antibodies recognizing the extracellular
part of the membrane proteins. FAT/CD36 clearly co-
localized together with PLAP at the plasma membrane in
the majority of cells and segregated from GFP-TMD (Fig-
ure 3). As expected [13] FATP4 showed an intracellular
pattern completely different from FAT/CD36. As it could
not be detected at the plasma membrane no co-patching
with FAT/CD36 (Figure 4) could be seen. This supports
again our previous data [13] that FATP4 is an enzyme at
the ER level, indirectly involved in fatty acid uptake due to
enzyme activity.
Antibody induced cross-linking increases the association of 
FAT/CD36 to detergent resistant membranes
Various proteins associate to lipid rafts with different
kinetics and partition coefficients [32]. It has been shown
that antibody-induced patching may stabilize association
of raft proteins with detergent-resistant membranes
(DRMs) [22,31]. We therefore analysed the association of
FAT/CD36 to DRMs under cross-linking with antibodies.
In initial experiments COS cells were transfected with
FAT/CD36 and then extracted with Triton X-100 and sub-
jected to OptiPrep™ step gradient centrifugation. Under
those conditions in three independent experiments no
significant effect of antibody cross-linking could be
detected. FAT/CD36 was found in both Triton X-100
resistant and soluble fractions showing that there are two
pools of FAT/CD36 in cellular membranes. However,
when FATP4 was co-expressed with FAT/CD36 raft associ-
ation of the FAT/CD36 was increased (Figure 5). Co-
Co-patching of PLAP and GFP-TMD (Podo) with FAT/CD36Figure 3
Co-patching of PLAP and GFP-TMD (Podo) with FAT/CD36. 20 h after transient transfection, Vero cells were incu-
bated for 45 min at 10°C with respective primary antibodies, washed and incubated for 45 min with mixed Cy5 and Cy3 fluo-
rescently-labelled secondary antibodies. PLAP and GFP-TMD were patched with polyclonal rabbit anti PLAP and polyclonal 
serum KG77 against GFP, respectively. Patching of FAT/CD36 was achieved with monoclonal antibody from Biosource interna-
tional. FAT/CD36 co-localized with the raft marker protein PLAP and segregated from GFP-TMD. Bar: 10 μm.Page 6 of 12
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FAT/CD36 does not co-localize with FATP4. 20 h after transient transfection with FAT/CD36 and FATP4-GFP, FAT/
CD36 was clustered with anti-FAT/CD36 antibody from Biosource and Cy3 fluorescently labelled secondary antibody. (A) 
FAT/CD36 is mainly localized at the plasma membrane. (B) FATP4-GFP shows a reticular staining pattern as described before 
[13] representing ER membranes. (C) Patched FAT/CD36 does not show any co-localisation with FATP4-GFP.
BMC Cell Biology 2008, 9:45 http://www.biomedcentral.com/1471-2121/9/45Figure 5Page 8 of 12
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(GFP) or the ER marker sec61-GFP [33] did not change
DRM association of FAT/CD36 (data not shown). Per-
forming cross-linking under co-expressing conditions
revealed a clearly increased fraction of FAT/CD36 in the
DRM fraction (Figure 5). Therefore, DRM association of
FAT/CD36 can be increased by cross-linking with anti-
bodies, which probably reflects increased raft affinity
caused by oligomerization. Similar results have been
demonstrated for other proteins, which by forming oli-
gomers increase their raft association [34-39]. The fact
that increased association of FAT/CD36 to DRMs occurs
especially in FATP4 overexpressing cells indicates a pro-
moting effect of FATP4 for FAT/CD36 raft association.
Cross-linking of FAT/CD36 with antibodies increases 
oleate uptake
If long chain fatty acid uptake were to take place in lipid
rafts, then antibody cross-linking should not only induce
co-patching with raft markers at the surface of living cells
and increase association between FAT/CD36 and DRMs. It
should also increase LCFA uptake, provided that the anti-
body does not neutralize LCFA binding or transport To
find this out, we analyzed the effect of antibody cross-
linking on overall [3H]-oleate uptake. Cells were co-trans-
fected with FATP4 and FAT/CD36 and [3H]-oleate uptake
analyzed within 5 min in the presence of anti-FAT/CD36
from Biosource (Figure 6). Antibody enhanced cross-link-
ing indeed increased [3H]-oleate uptake significantly. We
next examined the effect of cholesterol depletion on anti-
body-induced [3H]-oleate uptake. Immediately prior to
the uptake assay transfected cells were treated for 30 min
with 10 mM methyl-β-cyclodextrin and again uptake
within 5 min was analyzed. After cholesterol depletion
with methyl-β-cyclodextrin, [3H]-oleate uptake was no
longer enhanced by antibody cross-linking (Figure 6).
Thus, under conditions in which rafts are supposed to be
disrupted (cholesterol depletion) increased uptake of
[3H]-oleate due to cross-linking with antibodies is not
detectable. Thus, lipid raft integrity is important for FAT/
CD36 function in fatty acid uptake.
Discussion
The data presented here strengthen the evidence that FAT/
CD36 partition into lipid rafts and that LCFA uptake
mediated by FAT/CD36 depends on this association.
First of all, we could show that LCFA uptake was critically
dependent on the integrity of lipid rafts. Lipid rafts are
cholesterol and sphingolipid enriched microdomains.
Removal of raft lipids from cells leads to disruption of raft
functions [22]. Consistent with previous results on other
cells [14-17] we could demonstrate that by decreasing cel-
lular levels of cholesterol, LCFA uptake in COS cells was
also inhibited by > 50%. Additionally, we could show that
by decreasing ceramide synthesis with myriocin or deplet-
ing membrane sphingolipids using external sphingomy-
elinase we were able to lower LCFA uptake. Sphingolipid
depletion was less dramatic, probably because it is more
difficult to lower cellular sphingolipid levels than choles-
terol levels. The effects of sphingolipid synthesis inhibi-
tion may also be more pleiotropic because there are many
different kinds of sphingolipids (sphingomyelins and gly-
cosphingolipids). Nevertheless, we found that plasma
membrane GM1 levels were reduced after myriocin treat-
ment, demonstrating that not only cholesterol but also
sphingolipids modulate LCFA uptake.
Another important finding supporting raft association
was that after cross-linking with antibodies FAT/CD36 co-
patched with placental alkaline phosphatase (PLAP), a
GPI-anchored raft protein, in living cells and segregated
from patches formed by cross-linking of GFP-TMD that
served as a non-raft marker. This assay has previously been
used to monitor if proteins associate with lipid rafts at the
cell [25,39]. Antibody cross-linking of surface proteins
leads to the formation of plasma membrane clusters that
can be easily observed during light microscopy. It has
been shown that co-patching is dependent on plasma
membrane cholesterol, as patching is inhibited by choles-
terol removal [31].
Effect of antibody cross-linking on association of FAT/CD36 to DRMsFigure 5
Effect of antibody cross-linking on association of FAT/CD36 to DRMs. 20 h after transient transfection of FAT/CD36, 
FATP4 or both COS cells were were lysed in 1% Triton X-100/TNE at 4°C. (A) After floatation in an OptiPrep step-gradient 
FAT/CD36 was found in two pools, in DRMs and in soluble membranes (lane 1–3). Co-expression of FATP4 resulted in an 
increased relative amount of FAT/CD36 found in DRMs (lane 6). Antibody cross-linking of FAT/CD36 using an mouse anti 
human FAT/CD36 antibody from Biosource shifted FAT/CD36 towards the DRM fractions (lane 6). No significant amount of 
FATP4 was found in DRMs, indicating that FAT/CD36 and FATP4 might be in distinct compartments within the cell. Flotillin-2, 
a typical raft protein was used as a control to estimate the quality of DRM isolation. The results are representative of three 
others experiments carried out independently. (B) Quantification; FATP4 expression and antibody-induced patching signifi-
cantly increased the amount of FAT/CD36 in the top two fractions (DRM associated). The amount in the top two fractions 
was correlated to the total amount of protein in all fractions. Data are expressed as mean and SEM of n = 3 experiments. 
Asterisk indicates significant differences to cells transfected with FAT/CD36 only (p < 0.05).Page 9 of 12
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FAT/CD36 as was previously demonstrated for other raft
proteins [25,31]. Because a considerable amount of FAT/
CD36 was also found in the soluble fraction after deter-
gent treatment, FAT/CD36 is probably found (in steady
state) in two membrane pools, one raft associated and
another localized in the surrounding bilayer. How parti-
tioning between these two pools is regulated is an open
question, but interestingly it has been shown that FAT/
CD36 can dimerize [36]. Oligomerization of raft compo-
nents is known to lead to increased raft affinity [37,38].
Therefore this mechanism might be important to regulate
raft association of FAT/CD36.
It has been previously hypothesized that the detergent sol-
uble fraction might represent intracellular FAT/CD36 and
that upon cholesterol depletion FAT/CD36 might be stuck
in the secretory pathway to the plasma membrane [16]. It
has been described, that FAT/CD36 can indeed translocate
between the plasma membrane and intracellular com-
partments [40]. However, recent data from Covey et al
[17] using immunofluorescence and flow cytometry con-
vincingly show that in 3T3-L1 adipocytes cholesterol
depletion inhibits uptake of LCFAs without affecting FAT/
CD36 or caveolin-1 distribution within the cells, indicat-
ing that cholesterol levels regulate LFCA uptake via a path-
way that does not involve altered surface localization of
FAT/CD36. Our cross-linking data, which were obtained
on living cells at 10°C, can explain these findings because
under these conditions intracellular antigens are not
accessible to antibodies. Therefore increased DRM associ-
ation of FAT/CD36 (Figure 5) after cross-linking with anti-
bodies likely represent a horizontal recruitment of plasma
membrane non-raft associated FAT/CD36 into raft
domains. The enrichment of DRM associated FAT/CD36
could only be detected in presence of co-expressed FATP4.
Whether the FATP4 acitivity as acyl-CoA synthetase drives
cellular fatty acid influx and, thus, the requirement for raft
Effects of antibody cross-linking (x-link) and cholesterol depletion on [3H]-oleate uptakeFigure 6
Effects of antibody cross-linking (x-link) and cholesterol depletion on [3H]-oleate uptake. Cells were transiently 
transfected with FLAG-FAT/CD36 and FATP4 and then treated or not for 30 min with 10 mM methyl-β-cyclodextrin (MβCD). 
Afterwards overall [3H]-oleate uptake within the first 5 min in presence or absence of anti-FAT/CD36 from Biosource was 
analysed. Quantification of three independent experiments is shown. The ratio has been arbitrarily set to 100% in cells neither 
cross-linked nor cholesterol depleted. Cross-linking increased overall fatty acid uptake significantly (p < 0.05). However under 
conditions of cholesterol depletion, antibody enhanced fatty acid uptake was not apparent.Page 10 of 12
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involved in the raft constitution process remains to be elu-
cidated. FATP4 has been originally described to by a major
fatty acid transporter at the apical membrane of entero-
cytes [11] and it has been speculated that both proteins
might cooperate at the plasma membrane in fatty acid
uptake [5,41]. However recent data could not support this
view [13]. FATP4 seems rather to be an enzyme for acyl-
CoA activity at the ER level and therefore indirectly
increases fatty acid uptake. Deletion of FATP4 resulted in
a perinatal lethality with a phenotype reminiscent of
lethal restrictive dermopathy [42]. By histology the skin
was characterized by a hyperproliferative hyperkeratosis
with a disturbed epidermal barrier. Lipid analysis of the
skin revealed an increased proportion of ceramides and
cholesterol. Within the ceramide fraction very long chain
fatty acid substitutes were significantly reduced [42].
These finding suggests that FATP4 is involved in ceramide
biosynthesis, possibly by providing CoA activity for very
long chain fatty acids. It is intriguing to speculate that this
protein might therefore have also impact on lipid raft
integrity. Rafts are enriched in sphingolipids (that are
made from ceramides) and their long chain fatty acid sub-
stitutes have been implicated to be important to connect
the outer and the inner layer of the microdomain. FATP4
would therefore be indirectly involved in the fatty acid
uptake process by providing the molecules for a func-
tional lipid raft assembly. This could explain our results of
an enhanced raft association of FAT/CD36 after overex-
pression of FATP4.
In general clustering of lipid rafts can be achieved by dif-
ferent mechanisms [22]. Besides antibodies also other lig-
ands (e.g. insulin), lectins or linker proteins have been
discussed. Which would be a reasonable mechanism for
FAT/CD36 clustering? It is conceivable that under physio-
logical conditions the clustering of FAT/CD36 is mediated
by binding of long chain fatty acids. It was indeed shown
that the artificial, long chain fatty acid [3H]-sulfo-N-suc-
cinimidyl oleate (SSO) – when incubated with adipocytes
– binds to FAT/CD36 with high affinity and is almost
exclusively found in DRMs [16]. Thus the concentration
of fatty acids presented to the plasma membrane may reg-
ulate the rate of fatty acid uptake by providing a sufficient
functional platform in the form of FAT/CD36-raft com-
plexes.
Conclusion
Our data support a crucial role for lipid rafts in LCFA
uptake. Compartmentalization of FAT/CD36 at the cell
surface by lipid rafts seems to be important in regulating
its involvement in LCFA uptake. Taken all data together it
seems possible that fatty acid binding increases raft affin-
ity of FAT/CD36. The protein is shifted from the sur-
rounding bilayer to these microdomains were LCFA
uptake is likely to occur.
Abbreviations
LCFA: long chain fatty acids; SSO: sulfo-N-succinimidyl
oleate; DRM: detergent resistant membrane.
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